Business Wire

Sharjah Ruler Launches First 17 Volumes of ‘Historical Corpus of the Arabic Language’

3.11.2021 18:21:00 EET | Business Wire | Press release

Share

A historical cultural feat for the Arab world has been attained, as His Highness Sheikh Dr. Sultan bin Muhammad Al Qasimi, Member of the Supreme Council and Ruler of Sharjah, released the first 17 volumes of the Historical Corpus of the Arabic Language – the first-of-its kind project to chronicle 17 centuries of development in the Arabic language, in the presence of His Highness Sheikh Sultan bin Ahmed Al Qasimi, Crown Prince and Deputy Ruler of Sharjah.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211103005884/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

HH Ruler of Sharjah signs the copies of ‘Historical Corpus of the Arabic Language’ at the Sharjah International Book Fair (Photo: AETOSWire)

The Corpus volumes were unveiled by the Sharjah Ruler during the opening ceremony of the 40th edition of the Sharjah International Book Fair (SIBF) on Tuesday (2 November) at Expo Centre Sharjah, in the presence of a host of Arab ministers, presidents of Arabic language academies in the region and several Arabic scholars and researchers. HH Ruler of Sharjah also unveiled the official website of The Historical Corpus of the Arabic Language on this occasion.

In his keynote address, the Sharjah Ruler noted: “Arabic is one of the oldest living languages. We are here to celebrate Arabic language experts who gathered to work for years to document the roots and meanings of the Arabic language alphabet. We have started to work hard and bridge the gaps that existed in the documentation of the language. Finally, the sun has risen on this beautiful Corpus, which is the fruit of the efforts of a number of Arabic language institutions across the region.”

He added: “The role this detailed corpus will play in informing and educating students, researchers, and linguists and even the everyday language enthusiasts will be immense. I am not exaggerating when I say that there has been no other project that has attracted my attention or the attention of the Arab linguist community in our region to the extent that this project has. I am following up on the development of the efforts of everyone involved in this project, and I assure you that in the coming years we will be publishing several more volumes. I thank each and everyone involved in making this project a success.”

The Sharjah Ruler spoke about the online platform and smart phone applications that have been designed to make the Historical Corpus available digitally, and facilitate easy access to these resources from anywhere in the world. He also signed the copies of the first edition of the Historical Corpus of the Arabic Language at the SIBF 2021 opening ceremony.

The first volumes of the corpus are dedicated to the first five Arabic letters: the Hamza, ba, ta, tha and jeem and outline their evolution throughout the pre-Islamic period, the Islamic era from 1 AH to 132 AH, the Abbasid Caliphate from 133 AH to 656 AH, and the modern-day era from 1214 AH to date.

Dedicated website

The website dedicated to the Historical Corpus of the Arabic Language will offer scholars, linguists, researchers and language enthusiasts access to the 17 volumes of the corpus from anywhere in the world.

Champions of the Arabic language from across the region joined hands

The corpus has seen the collaboration of hundreds of researchers and linguists, editors and experts from 10 Arabic language academies across the Arab world, under the supervision of the Union of Arab Scientific Language Academies in Cairo, Egypt, and with the Arabic Language Academy in Sharjah managing the project’s executive committee. The corpus relies on a database of sources collected and digitised over the last four years, comprising 20,000 Arabic books, manuscripts, sources, and historical documents, including old inscriptions and archaeological finds.

The Historical Corpus of the Arabic Language is dedicated to providing key information about the history of Arabic lexicon, the original root of each word and all other words that are derived from the root with their vocal and phonetic changes. It traces the history of a given word and identifies the first user and evolution of that word from pre-Islamic Arabia all the way to the modern time. In this respect, it is different from any other dictionary because it cites living verses of the Holy Quran and Hadith of the Prophet, peace be upon him.

It also reveals the development of Arabic idioms and expressions through the centuries, and documents the entry of new words into Arabic language, lists words that are no longer used, and explains the reasons why. Besides, the corpus reviews the development of arts and sciences that directly relate to linguistics including grammar, morphology, philology, phonetics, rhetoric, rhyme, and so on.

It also offers comparative lexical reviews on Arabic and the influence it had on other Semitic languages such as Hebrew, Akkadian, Syriac, Abyssinian, and Amharic. An expert committee outlined the similarities and differences between Arabic words and the equivalent words in those languages, citing examples and documenting the bibliography and reference books that were used in the project.

Several senior officials were present during the launch, including Sheikh Nahyan bin Mubarak Al Nahyan, UAE Minister of Tolerance and Coexistence; Bodour Al Qasimi, President of the International Publishers Association; Sheikha Hoor Al Qasimi, President of the Sharjah Art Foundation; Sheikh Khalid bin Issam Al Qasimi, Chairman of the Department of Civil Aviation in Sharjah; Sheikh Salem bin Abdulrahman Al Qasimi, Chairman of the Sharjah Ruler's Office; Sheikha Nawar bint Ahmed Al Qasimi, Director, SAF; Abdul Rahman bin Mohammad Al Owais, UAE Minister of Health and Prevention.

The launch of the corpus’s 17 volumes was also witnessed by Dr. Salah Fadl, President of the Arab Language Academy in Cairo; Dr. Mamoun Wajeeh, Scientific Manager of the Historical Corpus of the Arabic Language; Dr. Abdulhamid Madkour, Secretary General of the Union of Arab Scientific Language Academies, and Secretary-General of the Arabic Language Academy in Cairo.

*Source: AETOSWire

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Hussain Al Mulla
Email: hussain.almulla@sgmb.ae
Phone: +97156 3980067

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye